Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.34 |
| ▸ | TUBB | P07437 | 2/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.34 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.34 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.34 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.34 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.34 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861149 | 0.88 | ADORA1 (0.34) | FYNADORA2AADORA1TUBB4ATUBB | |
| SCHEMBL2867613 | 0.86 | ADORA2A (0.39) | ADORA2AADORA1ADORA2BDPP4ACHE | |
| SCHEMBL2858897 | 0.84 | SRC (0.44) | ADORA2AADORA1PIK3CDRIPK2 | |
| SCHEMBL2860787 | 0.84 | ADORA1 (0.39) | ADORA2AADORA1ADORA2BDPP4ACHE | |
| SCHEMBL2858902 | 0.79 | ADORA2A (0.38) | FYNADORA2AADORA1ADORA2BDPP4 | |
| SCHEMBL27536115 | 0.78 | ALDH1A1 (0.41) | NPC1RAB9APTGER1 | |
| SCHEMBL2860001 | 0.76 | ADORA2A (0.42) | ADORA2AADORA1ADORA2BDPP4ACHE | |
| SCHEMBL4147011 | 0.75 | JAK2 (0.41) | ADORA2AADORA1CSNK1EPTGER1 | |
| SCHEMBL2872658 | 0.75 | ADORA2A (0.41) | ADORA2AADORA1ADORA2BDPP4ACHE | |
| SCHEMBL4137268 | 0.75 | DPP4 (0.42) | ADORA2AADORA1ADORA2BDPP4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | FYN 235/4885ADORA2A 3048/4885ADORA1 1820/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | FYN 353/4885ADORA2A 4348/4885ADORA1 2921/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | FYN 235/4885ADORA2A 3048/4885ADORA1 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.